Augmented drug preferentially eliminates cancer cells but do

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a "prodrug" -; a medicine designed to release its payload in a particular area of the body and in no other areas.

Related Keywords

Pavel Majer , Barbara Slusher , Emily Henderson , Jonathan Powell , Johns Hopkins Drug Discovery Program , Johns Hopkins Kimmel Cancer Center , Bloomberg Kimmel Institute For Cancer Immunotherapy , Study Co , Johns Hopkins University School Of Medicine , Dracen Pharmaceuticals Inc , Hopkins Medicine , Johns Hopkins Discovered , Johns Hopkins University School , Rais Phd , Study Co Author , Associate Professor , Johns Hopkins , Discovery Industry Focus , Kimmel Institute , Rana Rais , Johns Hopkins Drug Discovery , Cancer , Glutamine , Ancer Immunotherapy , Drug Discovery , Drugs , Efficacy , Immunotherapy , Medicine , Eurology , Mh , Pharmaceuticals , Harmacology , Research , Humor ,